Literature DB >> 7216485

Immune responses to labial infection of BALB/c mice with herpes simplex virus type 1.

P S Morahan, T A Thomson, S Kohl, B K Murray.   

Abstract

The kinetics of appearance of five humoral antibody responses (micro-neutralization assay [NT], complement fixation [CF], enzyme-linked immunosorbent assay [ELISA], radioimmunoassay [RIA], antibody-dependent cell-mediated cytotoxicity [ADCC]), were compared during labial infection of BALB/c mice with herpes simplex virus type 1 strain Patton. The ELISA/RIA antibody responses were present in most mice by day 5 after infection, at the beginning of the herpetic lip lesions; antibody effective in ADCC showed identical early kinetics. In contrast, NT/CF antibodies were not detected in most mice until day 10, at the time of resolution of the herpetic lip lesions. The humoral immune responses persisted for at least 6 months after infection. The NT and CF responses were closely correlated in time of appearance and titers (r = 0.9), as were the ELISA and RIA responses (r = 0.99). However, there was little correlation between NT/CF and ELISA/RIA responses (r = 0.02). The kinetics of the delayed type hypersensitivity response showed similar kinetics of appearance to the ELISA/RIA/ADCC humoral responses, and peaked similarly, but waned gradually over 2 months. The importance of antibody in protection against labial herpes simplex virus type 1 infection was demonstrated by the ability of passively transferred convalescent serum (that produced a minimum NT titer of 10 in recipient mice) to protect against development of herpetic lesions and death.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7216485      PMCID: PMC350604          DOI: 10.1128/iai.32.1.180-187.1981

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  25 in total

1.  Immunological response restricts number of cells in sensory ganglia infected with herpes simplex virus.

Authors:  M A Walz; H Yamamoto; A L Notkins
Journal:  Nature       Date:  1976-12-09       Impact factor: 49.962

2.  Latent infection of sensory ganglia with herpes simplex virus: efficacy of immunization.

Authors:  R W Price; M A Walz; C Wohlenberg; A L Notkins
Journal:  Science       Date:  1975-05-30       Impact factor: 47.728

3.  The role of antibody dependent cytotoxicity in recovery from herpesvirus infections.

Authors:  B T Rouse; R C Wardley; L A Babiuk
Journal:  Cell Immunol       Date:  1976-03-01       Impact factor: 4.868

4.  Role for cell-mediated immunity in the resistance of mice to subcutaneous herpes simplex virus infection.

Authors:  J E Oakes
Journal:  Infect Immun       Date:  1975-07       Impact factor: 3.441

5.  Host defense mechanisms against herpes simplex virus. II. Protection conferred by sensitized spleen cells.

Authors:  F A Ennis
Journal:  J Infect Dis       Date:  1973-06       Impact factor: 5.226

6.  Maintenance of latent herpetic infection: an apparent role for anti-viral IgG.

Authors:  J G Stevens; M L Cook
Journal:  J Immunol       Date:  1974-12       Impact factor: 5.422

7.  The mononuclear cell in human blood which mediates antibody-dependent cellular cytotoxicity to virus-infected target cells. II. Identification as a K cell.

Authors:  F M Melewicz; S L Shore; E W Ades; D J Phillips
Journal:  J Immunol       Date:  1977-02       Impact factor: 5.422

8.  Immunological basis for latency, recurrences and putative oncogenicity of herpes simplex virus.

Authors:  T Lehner; J M Wilton; E J Shillitoe
Journal:  Lancet       Date:  1975-07-12       Impact factor: 79.321

9.  Mechanism of immunologic resistance to herpes simplex virus 1 (HSV-1) infection.

Authors:  B Rager-Zisman; A C Allison
Journal:  J Immunol       Date:  1976-01       Impact factor: 5.422

10.  Cellular immunity to herpes simplex virus mediated by interferon.

Authors:  D L Lodmell; A L Notkins
Journal:  J Exp Med       Date:  1974-09-01       Impact factor: 14.307

View more
  7 in total

1.  Shared ancestry of herpes simplex virus 1 strain Patton with recent clinical isolates from Asia and with strain KOS63.

Authors:  Aldo Pourchet; Richard Copin; Matthew C Mulvey; Bo Shopsin; Ian Mohr; Angus C Wilson
Journal:  Virology       Date:  2017-12       Impact factor: 3.616

2.  Protection against lethal challenge of BALB/c mice by passive transfer of monoclonal antibodies to five glycoproteins of herpes simplex virus type 2.

Authors:  N Balachandran; S Bacchetti; W E Rawls
Journal:  Infect Immun       Date:  1982-09       Impact factor: 3.441

3.  Immunogenicity of herpes simplex virus glycoproteins gC and gB and their role in protective immunity.

Authors:  J Glorioso; C H Schröder; G Kumel; M Szczesiul; M Levine
Journal:  J Virol       Date:  1984-06       Impact factor: 5.103

4.  Expression of immunity to intravaginal herpes simplex virus type 2 infection in the genital tract and associated lymph nodes.

Authors:  M R McDermott; P L Brais; G C PLoettsche; M J Evelegh; C H Goldsmith
Journal:  Arch Virol       Date:  1987       Impact factor: 2.574

5.  Therapeutic activities of 1-(2-fluoro-2-deoxy-beta-D-arabinofuranosyl)-5-iodocytosine and -thymine alone and in combination with acyclovir and vidarabine in mice infected intracerebrally with herpes simplex virus.

Authors:  R F Schinazi; J Peters; M K Sokol; A J Nahmias
Journal:  Antimicrob Agents Chemother       Date:  1983-07       Impact factor: 5.191

6.  Comparison of effects of adjuvants on efficacy of virion envelope herpes simplex virus vaccine against labial infection of BALB/c mice.

Authors:  T A Thomson; J Hilfenhaus; H Moser; P S Morahan
Journal:  Infect Immun       Date:  1983-08       Impact factor: 3.441

7.  Recovery from lethal herpes simplex virus type 1 infection is mediated by cytotoxic T lymphocytes.

Authors:  H S Larsen; R G Russell; B T Rouse
Journal:  Infect Immun       Date:  1983-07       Impact factor: 3.441

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.